Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

CEL-SCI stock

CVM
US1508376076
A2DY0D

Price

0.76
Today +/-
-0.03
Today %
-4.69 %
P

CEL-SCI stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the CEL-SCI stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the CEL-SCI stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the CEL-SCI stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze CEL-SCI's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

CEL-SCI Stock Price History

DateCEL-SCI Price
11/6/20240.76 undefined
11/5/20240.80 undefined
11/4/20240.83 undefined
11/1/20240.87 undefined
10/31/20240.89 undefined
10/30/20240.90 undefined
10/29/20240.91 undefined
10/28/20240.92 undefined
10/25/20240.91 undefined
10/24/20240.90 undefined
10/23/20240.92 undefined
10/22/20240.92 undefined
10/21/20240.90 undefined
10/18/20240.90 undefined
10/17/20240.95 undefined
10/16/20240.99 undefined
10/15/20240.96 undefined
10/14/20241.00 undefined
10/11/20241.01 undefined
10/10/20241.01 undefined
10/9/20241.04 undefined
10/8/20241.05 undefined

CEL-SCI Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into CEL-SCI, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by CEL-SCI from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects CEL-SCI’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of CEL-SCI. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into CEL-SCI’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing CEL-SCI’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on CEL-SCI’s growth potential.

CEL-SCI Revenue, EBIT and net profit per share

DateCEL-SCI RevenueCEL-SCI EBITCEL-SCI Net Income
2028e300.98 M undefined78.98 M undefined50.93 M undefined
2027e157.66 M undefined-17.37 M undefined-9.32 M undefined
2026e7.78 M undefined-16.67 M undefined-14.91 M undefined
2025e3.08 M undefined-30.57 M undefined-27.53 M undefined
2024e87,536.7 undefined-39.12 M undefined-41.2 M undefined
20230 undefined-31.48 M undefined-32.37 M undefined
20220 undefined-36.06 M undefined-37.63 M undefined
20210 undefined-36.19 M undefined-36.71 M undefined
2020558,660 undefined-28.99 M undefined-30.28 M undefined
2019462,750 undefined-20.2 M undefined-22.13 M undefined
2018476,560 undefined-16.77 M undefined-31.85 M undefined
201769,020 undefined-21.34 M undefined-14.43 M undefined
2016285,060 undefined-23.65 M undefined-11.51 M undefined
2015657,380 undefined-32.39 M undefined-34.69 M undefined
2014260,000 undefined-27.57 M undefined-28.48 M undefined
2013160,000 undefined-19.87 M undefined-9.23 M undefined
2012250,000 undefined-17.24 M undefined-17.65 M undefined
2011960,000 undefined-17.99 M undefined-26.78 M undefined
2010150,000 undefined-18.56 M undefined8.95 M undefined
200980,000 undefined-12.02 M undefined-41.4 M undefined
200810,000 undefined-9.51 M undefined-8.13 M undefined
200760,000 undefined-9.35 M undefined-9.63 M undefined
2006130,000 undefined-5.35 M undefined-7.94 M undefined
2005270,000 undefined-4.08 M undefined-3.04 M undefined
2004330,000 undefined-4.13 M undefined-4.2 M undefined

CEL-SCI Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e
00000000001000000000000000000000000000000037157300
-------------------------------------------133.332,142.8691.08
----------------------------------------------
00000000000000000000000000000000000000-23-25000000
0-1-1-2-1-1000-1-2-4-3-6-8-6-7-8-10-6-4-4-4-5-9-9-12-18-17-17-19-27-32-23-21-16-20-28-36-36-31-39-30-16-1778
-----------200.00--------------------------------1,000.00-228.57-10.8326.00
0-1-1-2-1-1-10-1-1-2-4-3-6-8-8-7-8-11-9-6-4-3-7-9-8-418-26-17-9-28-34-11-14-31-22-30-36-37-32-41-27-14-950
---100.00-50.00-----100.00100.00-25.00100.0033.33--12.5014.2937.50-18.18-33.33-33.33-25.00133.3328.57-11.11412.50-119.51-425.00-34.62-47.06211.1121.43-67.6527.27121.43-29.0336.3620.002.78-13.5128.13-34.15-48.15-35.71-655.56
0.010.010.010.010.010.010.010.010.010.020.020.020.020.030.040.050.060.080.090.110.20.270.290.320.390.470.530.910.831.011.212.353.34.877.891731.1736.7640.6643.1544.4800000
----------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The CEL-SCI Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the CEL-SCI is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (k)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
19831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                                                 
0.040.4400.090.4200.020.030.0913.2210.526.074.0610.054.2512.495.9410.672.382.081.774.281.968.111.010.9335.1526.574.263.940.048.665.883.072.3710.318.4415.5142.2122.674.15
00000000.011.070.190000000000000000000.460.160.070.080.090.390.220.120.060.050.0500
00000000002201206080110700000000000000000000000000
000000000000000000000000.390.390.40.41.481.571.381.021.451.41.010.670.650.780.822.0122.25
0.050.030.020.10.10.160.070.120.120.040.060.090.350.410.70.790.591.840.870.630.380.510.430.530.040.030.041.052.731.961.381.450.980.980.980.360.521.3110.760.52
0.090.470.020.190.520.160.090.161.2813.4510.86.284.4710.545.0613.356.5312.513.252.712.154.792.399.0211.441.3635.5929.19.027.442.5111.648.355.464.2411.449.8117.745.2725.446.92
0.050.070.140.110.10.060.020.010.010.010.31.191.10.870.790.620.470.60.620.470.280.230.180.090.231.321.21.261.030.630.490.417.9517.3516.7916.2215.8320.8528.4124.7121.02
000000000000.010.540.020.020.020.020.140.140.14000.02001.58001.671.672.072.121.971.820000000
00000000000000000000000002000000000000005500
0000000000300270240450460440490530470420450470490510540590420360410380320320291.56256.55223.17258.09311.59313.42275.87212.2197.7
00000000000000000000000000000000000000000
0.050.970.5100.050.380.340.340.320.320.240.350000000000008.479.658.817.096.495.945.454.73001.671.671.671.671.910.162.39
0.11.040.650.110.150.440.360.350.330.330.841.821.881.341.271.080.981.271.231.030.730.70.690.69.2413.3410.438.719.68.628.337.5720.2119.4318.6918.1517.8122.8430.6525.0923.61
0.191.510.670.30.670.60.450.511.6113.7811.648.16.3511.886.3314.437.5113.784.483.742.885.493.089.6220.6814.746.0237.8118.6216.0610.8419.2128.5524.8922.9229.5927.6240.5475.9250.5230.53
                                                                                 
0.010.020.020.020.020.020.030.030.040.040.040.040.050.080.10.120.170.210.220.370.610.720.750.831.161.211.922.052.152.730.310.820.040.060.120.280.350.390.430.430.47
0.153.063.065.587.88.329.4910.4512.5526.5626.6126.8628.841.9244.4259.0459.6773.9375.6480.8787.1795.34100.36105.18130.08134.32173.02187.61194.44207.29218.55249.15269.07284.65296.3331.31358.51401.17474.3486.63499.83
-0.1-1.57-2.74-5.66-7.38-8.46-9.53-10.46-11.65-13.3-15.71-20.13-24.01-30.4-38.69-45.14-52.63-61.11-71.84-80.18-86.55-90.75-99-106.94-116.57-124.7-166.1-161.8-187.51-202.99-212.16-239.53-273.88-285.39-299.75-331.59-353.73-381.84-418.2-454.9-487.09
000000000000000000-0.0200-0.010000000000000000000
00000000000-0.090-0.020-0.05-0.12-0.0600000000000000000000000
0.061.510.34-0.060.44-0.12-0.010.020.9413.310.946.684.8411.585.8313.977.0912.9741.061.235.32.11-0.9314.6710.838.8427.869.087.036.710.44-4.76-0.68-3.3405.1319.7356.5332.1613.21
000.130.260.040.290.440.460.440.110.230.320.250.270.480.430.430.820.480.740.480.140.070.10.250.430.791.50.740.591.921.165.133.098.25.741.592.021.681.622.01
0000.090.110.010.01000.20.22000000000.150.10.060.080.170.20.190.150.270.310.210.50.860.450.921.630.970.741.131.221.451.8
000000000.160.10.05000000000.030.240.010.021.670.793.0235.120.420.0700.010.020.0200.022.510.690.210.4400
0.1200.1800000000000000001.140.8400000.21.111.16.11.11.11.11.100.99000000
000000.13000000.150.24000000000000000000.010.01000000.90.61.61.77
0.1200.310.350.150.430.450.460.60.410.50.470.490.270.480.430.430.820.482.061.660.210.171.941.243.8437.173.297.221.93.543.156.714.0110.849.233.024.273.944.665.59
00000.010.01000000.640.570000000.640.030000000000.020.0112.7813.0113.2113.3813.5111.7513.2511.729.95
00000000000000000000000000000000000000000
0000.010.060.2800.040.070.060.180.30.460.020.030.030.030.030.030.02000.818.654.830.010.016.652.327.130.575.6313.838.542.26.985.964.792.151.981.78
0000.010.070.2900.040.070.060.180.941.030.020.030.030.030.030.030.660.0300.818.654.830.010.016.652.327.130.595.6426.6121.5515.4220.3619.4716.5415.413.711.73
0.1200.310.360.220.720.450.50.670.470.681.411.520.290.510.460.460.850.512.721.690.210.9810.596.073.8537.189.949.549.034.138.7933.3225.5726.2629.5922.4920.8119.3418.3617.31
0.181.510.650.30.660.60.440.521.6113.7711.628.096.3611.876.3414.437.5513.824.513.782.925.513.099.6620.7414.6846.0237.818.6216.0610.8319.2328.5524.8922.9229.5927.6240.5475.8750.5230.53
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of CEL-SCI provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand CEL-SCI's financial health and stability.

Assets

CEL-SCI's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that CEL-SCI must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of CEL-SCI after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into CEL-SCI's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-1-1-10-1-1-2-4-3-6-8-6-7-8-10-8-6-4-3-7-9-7-4010-25-15-9-27-34-11-14-31-22-30-36-36-32
0000000000000000000000000000000002233
0000000000000000000000000000000000000
000000000000000000000-102-31203-16-2-4-102-1
000000000010001330003134-2583-4811-8-5221424292414
0000000000000000000000000000001,0001,0001,0001,0001,0001,0001,000
0000000000000000000000000000000000000
-10000-1-2-3-3-5-5-5-6-8-8-4-2-4-3-8-4-7-6-12-22-12-13-22-23-23-13-13-16-15-18-18-22
0000000-10000000000000-300000000000-2-900
00000-10142-65-860300000-7-200000000000-2-1550
00000-10152-65-860300000-70100000000000-660
0000000000000000000000000000000000000
000000000000000200080000-4-4000-12000-1-1-1
2000014001100140130008011514064169312121102114265406
20001140011101401303270141503960129312120132114255404
0000000000000001000400-200000000000100
0000000000000000000000000000000000000
00000301000004-5002-262-1032-6-220-38-2-207-1720-13-18
-1.84-0.59-0.54-0.74-0.92-1.44-2.48-4.95-3.68-5.35-6.11-5.92-6.37-8.81-8.76-4.25-2.55-4.45-3.14-8.68-5.07-11.32-7.21-13.33-22.78-12.24-13.65-23.03-23.91-23.11-13.8-13.39-16.5-17.97-27.8-18.88-23.21
0000000000000000000000000000000000000

CEL-SCI stock margins

The CEL-SCI margin analysis displays the gross margin, EBIT margin, as well as the profit margin of CEL-SCI. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for CEL-SCI.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the CEL-SCI's sales revenue. A higher gross margin percentage indicates that the CEL-SCI retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the CEL-SCI's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the CEL-SCI's total revenue generated. When comparing the revenue margin year over year, investors can gauge the CEL-SCI's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the CEL-SCI. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the CEL-SCI's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

CEL-SCI Margin History

CEL-SCI Gross marginCEL-SCI Profit marginCEL-SCI EBIT marginCEL-SCI Profit margin
2028e0 %26.24 %16.92 %
2027e0 %-11.02 %-5.91 %
2026e0 %-214.29 %-191.66 %
2025e0 %-994.12 %-895.38 %
2024e0 %-44,690.58 %-47,061.46 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %-5,188.32 %-5,419.57 %
20190 %-4,364.15 %-4,783.28 %
20180 %-3,519.44 %-6,683.64 %
20170 %-30,916.13 %-20,902.72 %
20160 %-8,295.38 %-4,038.62 %
20150 %-4,927.16 %-5,277.35 %
20140 %-10,603.85 %-10,953.85 %
20130 %-12,418.75 %-5,768.75 %
20120 %-6,896 %-7,060 %
20110 %-1,873.96 %-2,789.58 %
20100 %-12,373.33 %5,966.67 %
20090 %-15,025 %-51,750.01 %
20080 %-95,100.01 %-81,300 %
20070 %-15,583.33 %-16,050 %
20060 %-4,115.38 %-6,107.69 %
20050 %-1,511.11 %-1,125.93 %
20040 %-1,251.52 %-1,272.73 %

CEL-SCI Stock Sales Revenue, EBIT, Earnings per Share

The CEL-SCI earnings per share therefore indicates how much revenue CEL-SCI has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CEL-SCI earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CEL-SCI's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CEL-SCI’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CEL-SCI's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CEL-SCI Revenue, EBIT and net profit per share

DateCEL-SCI Sales per ShareCEL-SCI EBIT per shareCEL-SCI Earnings per Share
2028e4.89 undefined0 undefined0.83 undefined
2027e2.56 undefined0 undefined-0.15 undefined
2026e0.13 undefined0 undefined-0.24 undefined
2025e0.05 undefined0 undefined-0.45 undefined
2024e0 undefined0 undefined-0.67 undefined
20230 undefined-0.71 undefined-0.73 undefined
20220 undefined-0.84 undefined-0.87 undefined
20210 undefined-0.89 undefined-0.9 undefined
20200.02 undefined-0.79 undefined-0.82 undefined
20190.01 undefined-0.65 undefined-0.71 undefined
20180.03 undefined-0.99 undefined-1.87 undefined
20170.01 undefined-2.7 undefined-1.83 undefined
20160.06 undefined-4.86 undefined-2.37 undefined
20150.2 undefined-9.81 undefined-10.51 undefined
20140.11 undefined-11.73 undefined-12.12 undefined
20130.13 undefined-16.42 undefined-7.63 undefined
20120.25 undefined-17.07 undefined-17.48 undefined
20111.16 undefined-21.67 undefined-32.27 undefined
20100.16 undefined-20.4 undefined9.84 undefined
20090.15 undefined-22.68 undefined-78.11 undefined
20080.02 undefined-20.23 undefined-17.3 undefined
20070.15 undefined-23.97 undefined-24.69 undefined
20060.41 undefined-16.72 undefined-24.81 undefined
20050.93 undefined-14.07 undefined-10.48 undefined
20041.22 undefined-15.3 undefined-15.56 undefined

CEL-SCI business model

CEL-SCI Corp is a biotechnology company specializing in the development of immunotherapies for the treatment of cancer and infectious diseases. The company was founded in 1983 and is headquartered in Virginia, USA. CEL-SCI is one of the most popular companies on Eulerpool.com.

CEL-SCI SWOT Analysis

Strengths

CEL-SCI Corp has a strong intellectual property portfolio with several patents and proprietary technologies.

The company has a dedicated and experienced research and development team.

CEL-SCI Corp has developed a potential breakthrough therapy for certain diseases.

Weaknesses

The company has a relatively small market presence compared to its competitors.

CEL-SCI Corp heavily relies on the success of its lead product, increasing the risk associated with its development.

Limited financial resources and funding options may pose a challenge for future growth.

Opportunities

Growing demand for innovative therapies in the healthcare industry presents an opportunity for CEL-SCI Corp.

Expansion into new geographic markets can help the company capture untapped growth potential.

Collaboration with larger pharmaceutical companies can provide access to additional resources and expertise.

Threats

Regulatory approval processes can be time-consuming and cost-intensive, potentially delaying product commercialization.

Intense competition from established pharmaceutical companies can hinder market penetration.

Uncertainty related to changes in healthcare policies and reimbursement systems may impact the profitability of CEL-SCI Corp.

CEL-SCI Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

CEL-SCI historical P/E ratio, EBIT multiple, and P/S ratio

CEL-SCI shares outstanding

The number of shares was CEL-SCI in 2023 — This indicates how many shares 44.48 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue CEL-SCI earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates CEL-SCI's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of CEL-SCI’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating CEL-SCI's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

CEL-SCI stock splits

In CEL-SCI's history, there have been no stock splits.

The World’s Best Investors Are On Eulerpool

Unfortunately, there are currently no price targets and forecasts available for CEL-SCI.

CEL-SCI latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.13 -0.14  (-6.63 %)2024 Q3
3/31/2024-0.14 -0.14  (0.99 %)2024 Q2
9/30/2023-0.16 -0.16  (0.99 %)2023 Q4
6/30/2023-0.16 -0.19  (-16.96 %)2023 Q3
3/31/2023-0.17 -0.19  (-10.66 %)2023 Q2
12/31/2022-0.21 -0.18  (15.13 %)2023 Q1
9/30/2022-0.2 -0.21  (-3.96 %)2022 Q4
6/30/2022-0.19 -0.23  (-19.85 %)2022 Q3
3/31/2022-0.18 -0.23  (-30.09 %)2022 Q2
3/31/2021-0.19 -0.28  (-45.91 %)2021 Q2
1
2
3

Eulerpool ESG Scorecard© for the CEL-SCI stock

Eulerpool World ESG Rating (EESG©)

48/ 100

🌱 Environment

54

👫 Social

24

🏛️ Governance

64

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

CEL-SCI shareholders

%
Name
Stocks
Change
Date
3.92136 % The Vanguard Group, Inc.2,411,246217,9196/30/2024
1.95910 % Kersten (Geert R)1,204,6524,8829/30/2024
1.24425 % BlackRock Institutional Trust Company, N.A.765,0918,7786/30/2024
0.90906 % Geode Capital Management, L.L.C.558,98294,5736/30/2024
0.72804 % Osaic Holdings, Inc.447,673139,4956/30/2024
0.39042 % Prichep (Patricia B)240,0714,0479/30/2024
0.31470 % State Street Global Advisors (US)193,507-5006/30/2024
0.28265 % Renaissance Technologies LLC173,80040,0006/30/2024
0.22241 % Thoroughbred Financial Services LLC136,76180,0016/30/2024
0.19743 % UBS Financial Services, Inc.121,40169,0826/30/2024
1
2
3
4
5
...
10

CEL-SCI Executives and Management Board

Mr. Geert Kersten(64)
CEL-SCI Chief Executive Officer, Chief Financial Officer, Treasurer, Director (since 1995)
Compensation 2.25 M
Dr. Eyal Talor(66)
CEL-SCI Chief Scientific Officer
Compensation 895,065
Ms. Patricia Prichep(71)
CEL-SCI Senior Vice President - Operations, Corporate Secretary
Compensation 803,160
Dr. Daniel Zimmerman(81)
CEL-SCI Senior Vice President - Research, Cellular Immunology
Compensation 518,131
Mr. John Cipriano(81)
CEL-SCI Senior Vice President - Regulatory Affairs
Compensation 433,704
1
2

Most common questions regarding CEL-SCI

What values and corporate philosophy does CEL-SCI represent?

CEL-SCI Corp is a biotechnology company that focuses on the development and commercialization of immunotherapy products for the treatment of cancer and infectious diseases. The company's core values revolve around innovation, scientific excellence, and a commitment to improving patient outcomes. With a corporate philosophy rooted in advancing immunotherapy through cutting-edge research and development, CEL-SCI Corp strives to bring novel and effective treatments to market to address unmet medical needs. By harnessing the power of the immune system, the company aims to revolutionize the field of immunotherapy and positively impact the lives of patients globally.

In which countries and regions is CEL-SCI primarily present?

CEL-SCI Corp is primarily present in the United States.

What significant milestones has the company CEL-SCI achieved?

CEL-SCI Corp, a reputable biotechnology company, has achieved several significant milestones throughout its history. Notably, the company successfully developed its revolutionary investigational therapy, Multikine, which has shown promising results in clinical trials. CEL-SCI Corp also obtained patents for its unique platform technology, LEAPS (Ligand Epitope Antigen Presentation System), which has the potential to treat various infectious diseases and autoimmune disorders. Furthermore, the company received multiple grants, recognizing its research excellence and commitment to medical advancements. These milestones highlight CEL-SCI Corp's dedication to innovation and breakthrough therapies in the biotechnology industry.

What is the history and background of the company CEL-SCI?

CEL-SCI Corp is a biotechnology company with over 30 years of history and expertise. Founded in 1983, the company focuses on developing immunotherapy products to treat cancer and infectious diseases. CEL-SCI Corp's flagship product, Multikine, is an investigational immunotherapy that aims to target advanced primary head and neck cancer. The company has conducted numerous clinical trials to evaluate Multikine's efficacy and safety. CEL-SCI Corp has also collaborated with renowned research institutions and received grants from prestigious organizations. With its dedication to advancing innovative immunotherapy, CEL-SCI Corp strives to make significant contributions to the field of medical science and improve patient outcomes.

Who are the main competitors of CEL-SCI in the market?

The main competitors of CEL-SCI Corp in the market are other biotechnology companies that operate in the same field. These include companies such as Athersys, Inc., Heat Biologics, Inc., and Inovio Pharmaceuticals, Inc.

In which industries is CEL-SCI primarily active?

CEL-SCI Corp is primarily active in the biotechnology industry.

What is the business model of CEL-SCI?

The business model of CEL-SCI Corp is centered around the development and commercialization of immunotherapy products for the treatment of various diseases, including cancer and infectious diseases. The company focuses on its lead product candidate, Multikine, which is being developed as a potential treatment for head and neck cancer. CEL-SCI Corp aims to utilize the immune system to activate a targeted response against tumors through its unique immunotherapy approach. By advancing innovative and scientifically backed solutions, CEL-SCI Corp strives to provide effective and transformative therapies that can significantly impact patient outcomes and address unmet medical needs in the field of immunotherapy.

What is the P/E ratio of CEL-SCI 2024?

The CEL-SCI P/E ratio is -0.82.

What is the P/S ratio of CEL-SCI 2024?

The CEL-SCI P/S ratio is 387.88.

What is the Quality Investing of CEL-SCI?

The Quality Investing for CEL-SCI is 2/10.

What is the revenue of CEL-SCI 2024?

The expected CEL-SCI revenue is 87,536.7 USD.

How high is the profit of CEL-SCI 2024?

The expected CEL-SCI profit is -41.2 M USD.

What is the business model of CEL-SCI

CEL-SCI Corporation is a biopharmaceutical company specializing in the development of immunotherapies for the treatment of cancer and certain infectious diseases. The company is headquartered in Virginia, USA, and is listed on the NYSE American stock exchange. The business model of CEL-SCI Corp consists of three main components: research and development, clinical development, and commercialization. The company has a wide range of products in various stages of development. Research and Development: CEL-SCI Corp focuses on the research and development of immunotherapies for cancer and infectious diseases. The company harnesses the patient's immune system to attack and destroy cancer cells. CEL-SCI has developed the Multikin Immunomodulator technology program, which aims to elicit specific immune responses in the body to prevent tumor growth and activate the immune system. Clinical Development: CEL-SCI Corp conducts Phase III clinical trials to confirm the effectiveness and safety of its immunotherapies. The company's main focus is on head and neck cancer, targeting a difficult-to-treat patient population with high relapse rates. The studies have yielded positive results, highlighting the potential of CEL-SCI Corp's immunotherapy. Commercialization: CEL-SCI aims to bring innovative immunotherapies to the market. The company enters into licensing agreements and strategic partnerships with other pharmaceutical companies to extend the benefits of its technology to other types of cancer and enable global distribution. CEL-SCI Corp has several products in its portfolio at various stages of clinical development. Currently, the company is focused on the clinical development of its leading therapy, Multikin Immunomodulator L.E.A.P.S. (Ligand Epitope Antigen Presentation System), used for the treatment of head and neck cancer. The company has also developed a technology platform called "LEAPS" that can identify specific antigens and activate the patient's immune system. This is advantageous as it has the potential to treat various types of cancer that have specific antigens, thereby creating personalized medicine. In summary, CEL-SCI Corp is developing innovative immunotherapies for the treatment of cancer and infectious diseases. The company builds upon extensive research and development to conduct Phase III clinical trials and ultimately commercialize its products. Overall, CEL-SCI Corp's business strategy shows strong growth prospects and promising opportunities in the healthcare sector.

What is the CEL-SCI dividend?

CEL-SCI pays a dividend of 0 USD distributed over payouts per year.

How often does CEL-SCI pay dividends?

The dividend cannot currently be calculated for CEL-SCI or the company does not pay out a dividend.

What is the CEL-SCI ISIN?

The ISIN of CEL-SCI is US1508376076.

What is the CEL-SCI WKN?

The WKN of CEL-SCI is A2DY0D.

What is the CEL-SCI ticker?

The ticker of CEL-SCI is CVM.

How much dividend does CEL-SCI pay?

Over the past 12 months, CEL-SCI paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, CEL-SCI is expected to pay a dividend of 0 USD.

What is the dividend yield of CEL-SCI?

The current dividend yield of CEL-SCI is .

When does CEL-SCI pay dividends?

CEL-SCI pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of CEL-SCI?

CEL-SCI paid dividends every year for the past 0 years.

What is the dividend of CEL-SCI?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is CEL-SCI located?

CEL-SCI is assigned to the 'Health' sector.

Wann musste ich die Aktien von CEL-SCI kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of CEL-SCI from 11/6/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 11/6/2024.

When did CEL-SCI pay the last dividend?

The last dividend was paid out on 11/6/2024.

What was the dividend of CEL-SCI in the year 2023?

In the year 2023, CEL-SCI distributed 0 USD as dividends.

In which currency does CEL-SCI pay out the dividend?

The dividends of CEL-SCI are distributed in USD.

All fundamentals about CEL-SCI

Our stock analysis for CEL-SCI Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of CEL-SCI Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.